Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - glyphosate present as the potassium salt - aqueous concentrate - glyphosate present as the potassium salt glycine active 540.0 g/l - herbicide

Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

oz crop pty ltd - dicamba present as the dimethylamine salt; mcpa present as the dimethylamine salt - soluble concentrate - dicamba present as the dimethylamine salt benzoic acid-arylaliphatic active 80.0 g/l; mcpa present as the dimethylamine salt phenoxy acids-mcpa-amine active 340.0 g/l - herbicide

Estats Units - anglès - NLM (National Library of Medicine)

specgx llc - dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate monohydrate (unii: o1zpv620o4) (amphetamine - unii:ck833kgx7e), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd). the efficacy of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in the treatment of adhd was established on the basis of two controlled trials in children aged 6 to 12, one controlled trial in adolescents aged 13 to 17, and one controlled trial in adults who met dsm-iv® criteria for adhd [see clinical studies (14)] . a diagnosis of adhd (dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. for the hyperactive-impulsive type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; "on the go;" excessive talking; blurting answers; can't wait turn; intrusive. the combined type requires both inattentive and hyperactive-impulsive criteria to be met. special diagnostic considerations specific etiology of this syndrome is unknown, and there is no single diagnostic test. adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. learning may or may not be impaired. the diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presence of the required number of dsm-iv® characteristics. need for comprehensive treatment program dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are indicated as an integral part of a total treatment program for adhd that may include other measures (psychological, educational, social) for patients with this syndrome. drug treatment may not be indicated for all patients with this syndrome. stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. appropriate educational placement is essential and psychosocial intervention is often helpful. when remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the child's symptoms. long-term use the effectiveness of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules for long-term use, i.e., for more than 3 weeks in children and 4 weeks in adolescents and adults, has not been systematically evaluated in controlled trials. therefore, the physician who elects to use dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules administration is contraindicated in patients with the following conditions: - advanced arteriosclerosis - symptomatic cardiovascular disease - moderate to severe hypertension - hyperthyroidism - in patients known to be hypersensitive to amphetamine, or other components of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see adverse reactions (6.2)] . - glaucoma - agitated states - history of drug abuse - patients taking monoamine oxidase inhibitors (maois), or within 14 days of stopping maois (including maois such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive crisis [see warnings and precautions (5.7) and drug interactions (7.1)] pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychostimulants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/othermedications/. risk summary available data from published epidemiologic studies and postmarketing reports on use of prescription amphetamine in pregnant women have not identified a drug-associated risk of major birth defects and miscarriage (see data) . adverse pregnancy outcomes, including premature delivery and low birth weight, have been seen in infants born to mothers taking amphetamines during pregnancy (see clinical considerations) . no apparent effects on morphological development were observed in embryo-fetal development studies, with oral administration of amphetamine to rats and rabbits during organogenesis at doses 2 and 12 times, respectively, the maximum recommended human dose (mrhd) of 20 mg/day given to adolescents, on a mg/m2 basis. however, in a pre- and post-natal development study, amphetamine (d - to l - ratio of 3:1) administered orally to pregnant rats during gestation and lactation caused a decrease in pup survival and a decrease in pup body weight that correlated with a delay in developmental landmarks at clinically relevant doses of amphetamine. in addition, adverse effects on reproductive performance were observed in pups whose mothers were treated with amphetamine. long-term neurochemical and behavioral effects have also been reported in animal developmental studies using clinically relevant doses of amphetamine (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations fetal/neonatal adverse reactions amphetamines, such as dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, cause vasoconstriction and thereby may decrease placental perfusion. in addition, amphetamines can stimulate uterine contractions, increasing the risk of premature delivery. infants born to mothers taking amphetamines during pregnancy have an increased risk of premature delivery and low birth weight. monitor infants born to mothers taking amphetamines for symptoms of withdrawal such as feeding difficulties, irritability, agitation, and excessive drowsiness. data animal data amphetamine (d - to l -enantiomer ratio of 3:1) had no apparent effects on embryofetal morphological development or survival when administered orally to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. these doses are approximately 2 and 12 times, respectively, the maximum recommended human dose (mrhd) of 20 mg/day given to adolescents, on a mg/m2 basis. fetal malformations and death have been reported in mice following parenteral administration of d -amphetamine doses of 50 mg/kg/day (approximately 10 times the mrhd given to adolescents on a mg/m2 basis) or greater to pregnant animals. administration of these doses was also associated with severe maternal toxicity. a study was conducted in which pregnant rats received daily oral doses of amphetamine (d - to l­ -enantiomer ratio of 3:1) of 2, 6, and 10 mg/kg from gestation day 6 to lactation day 20. these doses are approximately 0.8, 2, and 4 times the mrhd of 20 mg/day given to adolescents, on a mg/m2 basis. all doses caused hyperactivity and decreased weight gain in the dams. a decrease in pup survival was seen at all doses. a decrease in pup body weight was seen at 6 and 10 mg/kg which correlated with delays in developmental landmarks, such as preputial separation and vaginal opening. increased pup locomotor activity was seen at 10 mg/kg on day 22 postpartum but not at 5 weeks postweaning. when pups were tested for reproductive performance at maturation, gestational weight gain, number of implantations, and number of delivered pups were decreased in the group whose mothers had been given 10 mg/kg. a number of studies from the literature in rodents indicate that prenatal or early postnatal exposure to amphetamine (d - or d , l -) at doses similar to those used clinically can result in long-term neurochemical and behavioral alterations. reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function. risk summary based on limited case reports in published literature, amphetamine (d - or d , l -) is present in human milk, at relative infant doses of 2% to 13.8% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.9 and 7.5. there are no reports of adverse effects on the breastfed infant. long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. it is possible that large dosages of amphetamine might interfere with milk production, especially in women whose lactation is not well established. because of the potential for serious adverse reactions in nursing infants, advise patients that breastfeeding is not recommended during treatment with dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules. dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are indicated for use in children 6 years of age and older. the safety and efficacy of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules in children under 6 years of age have not been studied. long-term effects of amphetamines in children have not been well established. long-term growth suppression growth should be monitored during treatment with stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, and pediatric patients aged 6 to 17 years who are not growing or gaining weight as expected may need to have their treatment interrupted [see warnings and precautions (5.4)]. juvenile animal toxicity data juvenile rats treated with mixed amphetamine salts early in the postnatal period through sexual maturation demonstrated transient changes in motor activity. learning and memory was impaired at approximately 6 times the maximum recommended human dose (mrhd) given to children on a mg/m2 basis. no recovery was seen following a drug free period. a delay in sexual maturation was observed at a dose approximately 6 times the mrhd given to children on a mg/m2 basis, although there was no effect on fertility. in a juvenile developmental study, rats received daily oral doses of amphetamine (d-  to l- enantiomer ratio of 3:1) of 2, 6, or 20 mg/kg on days 7-13 of age; from day 14 to approximately day 60 of age these doses were given b.i.d. for total daily doses of 4, 12, or 40 mg/kg. the latter doses are approximately 0.6, 2, and 6 times the mrhd of 30 mg/day, given to children on a mg/m2 basis. post dosing hyperactivity was seen at all doses; motor activity measured prior to the daily dose was decreased during the dosing period but the decreased motor activity was largely absent after an 18 day drug-free recovery period. performance in the morris water maze test for learning and memory was impaired at the 40 mg/kg dose, and sporadically at the lower doses, when measured prior to the daily dose during the treatment period; no recovery was seen after a 19 day drug-free period. a delay in the developmental milestones of vaginal opening and preputial separation was seen at 40 mg/kg but there was no effect on fertility. dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules have not been studied in the geriatric population. due to reduced clearance of amphetamines in patients with severe renal impairment (gfr 15 to <30 ml/ min/1.73m2 ), the recommended dose should be reduced. dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are not recommended in patients with esrd (gfr < 15 ml/min/1.73m2 ) [see dosage and administration (2.6), clinical pharmacology (12.3)] . d-amphetamine is not dialyzable. dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are a schedule ii controlled substance. dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules is a cns stimulant that contains amphetamine, which has a high potential for abuse. abuse is characterized by impaired control of drug use, compulsive use despite harm, and craving. signs and symptoms of amphetamine abuse may include increased heart rate, respiratory rate, blood pressure, and/or sweating, dilated pupils, hyperactivity, restlessness, insomnia, decreased appetite, loss of coordination, tremors, flushed skin, vomiting, and/or abdominal pain. anxiety, psychosis, hostility, aggression, suicidal or homicidal ideation have also been observed. abusers of amphetamines may use other unapproved routes of administration which can result in overdose and death [see overdosage (10)]. to reduce the abuse of cns stimulants, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules, assess the risk of abuse prior to prescribing. after prescribing, keep careful prescription records, educate patients and their families about abuse and proper storage and disposal of cns stimulants. monitor for signs of abuse while on therapy and re-evaluate the need for dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules use. tolerance (a state of adaptation in which exposure to a specific dose of a drug results in a reduction of the drug’s desired and/or undesired effects over time, in such a way that a higher dose of the drug is required to produce the same effect that was once obtained at a lower dose) may occur during chronic therapy of cns stimulants including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules. physical dependence (which is manifested by a withdrawal syndrome produced by abrupt cessation, rapid dose reduction, or administration of an antagonist) may occur in patients treated with cns stimulants including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules. withdrawal symptoms after abrupt cessation of cns stimulants include dysphoric mood; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.

Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agri west pty limited - glyphosate present as the mono-ammonium salt - water soluble granules - glyphosate present as the mono-ammonium salt glycine active 700.0 g/kg - herbicide - agricultural/farm buildings | almond | annual grass weed - seed set control | avocado | banana | blueberry | buildings - around - african lovegrass | african turnip weed | amaranth or amaranthus | amsinckia | annual phalaris | annual ryegrass | annual weeds | artichoke thistle | australian bluebell - w. gracilis | bamboo | barley grass | barnyard or water grass | bathurst burr | bent grass - agrostis spp. | bitou bush or boneseed | blackberry | bladder ketmia | blady grass | boggabri weed | boxthorn | bracken | brome grass | burr medic | calomba daisy | caltrop or yellow vine | camel or afghan melon | canary grass | capeweed | carpet grass | cat's ear or flatweed | chickweed | chinese scrub | cobbler's pegs | cocksfoot | columbus grass - seedling | couch | cudweed | cumbungi | deadnettle | dock | dock - seedling | english couch or rope twitch | erodium, crowfoot or storksbill | eucalyptus - seedling up to 2 m tall | fumitory | furze or gorse | giant or black pigweed | glyceria or reed sweet grass | gooseberry | ground cherry - physalis angulata | groundsel bush | guinea grass | hawthorn | hedge or wild mustard | hoary cress or whiteweed

Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agri west pty limited - imazapic as the ammonium salt - soluble concentrate - imazapic as the ammonium salt imidazolinone active 240.0 g/l - herbicide - peanut | prior to winter crop | sugar cane | by cultivation and/or sowing | inter-row spraying | prior to disturbance | ratoon s - awnless barnyard grass | barnyard grass or water grass | barnyard or water grass | blackberry nightshade | blue billygoat weed | boggabri weed | button grass | caltrop or yellow vine | common pigweed | common sida | cowvine | crowsfoot grass | giant or black pigweed | glossy nightshade | green amaranth | green summer grass | guinea grass | ipomoea spp. | liverseed or urochloa grass | milkweed | mintweed | native millet | nutgrass | stink grass | summer grass | amaranthus mitchellii | australian millet | barnyard grass | bellvine | bindy-eye | black nightshade | black pigweed | blowaway grass | blue salvia | blue top | bullhead | bull's head | caltrop burr | cathead | cat's-head | coast button grass | convolvulus | crab grass | dactyloctenium aegyptium | giant pigweed | goat's-head | green summergrass | liverseed grass | love grass | mexican fire plant | mint weed | paddy lucerne | paddy's lucerne | peachvine | puncture vine | salvia lanceolata | sida retusa | sida weed | star of bethlehem | tribulus maximus |

Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

4 farmers australia pty ltd - picloram as the triisopropanolamine salt; 2,4-d as the triisopropanolamine salt - soluble concentrate - picloram as the triisopropanolamine salt anilide/aniline-pyrimidine active 75.0 g/l; 2,4-d as the triisopropanolamine salt phenoxy acids-2,4-d-amine active 300.0 g/l - herbicide - barley | canary grass | commercial/industrial land | fallow or stubble,prior to winter cereal | maize | oats | pasture | rights - african boxthorn | alkaki or ivyleaf sida | amaranth or amaranthus | amsinckia | apple-of-sodom | artichoke thistle | bathurst burr | bellvine | bindweed | bitou bush or boneseed | black bindweed | black knapweed | blackberry | bladder campion | bladder ketmia | blue heliotrope or blue top | borreria | boxthorn | broadleaf weeds | brooms | burr ragweed | californian thistle | caltrop or yellow vine | camelthorn | cape honey flower | cape or montpellier broom | chilean cestrum | chinese scrub | climbing buckwheat | cobbler's pegs | colocynth | common heliotrope | creeping/russian knapweed,hardhead | crofton weed | cutleaf mignonette | datura spp. | devil's-fig | dock | dog rose | english broom | eucalyptus | fat hen | furze or gorse | giant or black pigweed | golden thistle | gooseberry | groundsel bush | hawthorn | hoary cress or whiteweed | inkweed | khaki weed | lantana spp. | limebush | lucerne | mayne's pest | melilotus or hexham scent | mexican poppy | mintweed | mistflower or creeping crofton weed | mor

Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

oz crop pty ltd - 2,4-d present as the isopropylamine salt - aqueous concentrate - 2,4-d present as the isopropylamine salt phenoxy acids-2,4-d-amine active 300.0 g/l - herbicide - balansa clover (prior to sowing) | barley | barley - prior to sowing | broom millet | canola (prior to sowing) | cereal rye | ch - amaranth or amaranthus | amsinckia | annual thistle | apple-of-peru | artichoke thistle | australian bindweed - seedling | ball mustard | bathurst burr | bathurst burr - seedling | bellvine - seedling | billygoat weed or blue top | bindweed | bindy-eye | bitou bush or boneseed | blackberry nightshade | blackberry nightshade - seedling | bladder ketmia | blue snakeweed | blue top - ageratum/heliotropium spp. | boxthorn | broadleaf weeds - except noogoora burr | burr medic | californian burr | californian burr seedling | californian thistle | caltrop or yellow vine | caltrop or yellow vine - seedling | camel or afghan melon | canola - brassica napus | cape tulip | capeweed | capeweed - seedling | cat's ear or flatweed | charlock | chinese mint | clockweed | clover | cobbler's pegs | common heliotrope | common iceplant | common storksbill | common vetch or tares | convolvulus vines | cowvine | desiccate broadleaf weeds | dock | dock - seedling | doveweed | fat hen | fleabane | fumitory - red | fumitory - white |

Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - chlorsulfuron - water dispersible granule - chlorsulfuron urea-sulfonyl active 750.0 g/kg - herbicide - barley | cereal rye | oats | triticale | wheat - african turnip weed | amsinckia,yellow burrweed or burr grass | annual or wimmera ryegrass | annual phalaris | annual ryegrass | ball mustard | barley grass | bifora, carrot weed or bird's eye | black bindweed | brome grass - suppression | cape tulip | capeweed | charlock | common iceplant | corn gromwell, ironweed or sheepweed | deadnettle | denseflower fumitory | dock | erodium spp. | fat hen | fumitory | hoary cress or whiteweed | indian hedge mustard | lincoln weed, sand rocket or mustard | loosestrife | matricaria | melilotus or hexham scent | mintweed | mouse-ear chickweed | mustard | new zealand spinach | onion or guildford grass | paradoxa grass | paterson's curse | pimpernels | prickly lettuce | rough poppy | saffron thistle - suppression | saltbush | shepherd's purse | silvergrass - vulpia spp. | slender celery | soursob or oxalis | spear or black thistle | stagger weed | stemless thistle | three cornered jack or doublegee | tree hogweed | turnip weed | wild radish or radish weed | wild turnip | wir

Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - mcpa present as the dimethylamine salt - aqueous concentrate - mcpa present as the dimethylamine salt phenoxy acids-mcpa-amine active 500.0 g/l - herbicide - barley | cereal rye | commercial/industrial land | fallow land | flax | grass pasture | grass seed crop | high volume spraying | - amsinckia | amsinckia,yellow burrweed or burr grass | annual thistle | artichoke thistle | ball mustard | bathurst burr | bellvine | bindweed | black bindweed | blue top - ageratum/heliotropium spp. | californian burr | caltrop or yellow vine | cape tulip | capeweed | carrot weed | cat's ear or flatweed | charlock | chinese burr | common iceplant | common morning glory | corn gromwell, ironweed or sheepweed | cutleaf mignonette | dandelion - hypochaeris glabra | deadnettle | dock | dock - seedling | erodium spp. | fat hen | fennel | field bindweed | field cress | flannel weed | fumitory - red | gambia pea | geranium | hedge or wild mustard | hoary cress or whiteweed | horehound | horehound - established | horehound - seedling | iceplant | lesser swinecress or bittercress | lincoln weed, sand rocket or mustard | london rocket | lupins | melilotus or hexham scent | merremia vine | mintweed | mustard | nodding thistle | noogoora burr | opium poppy | paterson's curse | pimpernels | pink convolvulus | plantain | r

Austràlia - anglès - APVMA (Australian Pesticides and Veterinary Medicines Authority)

axichem pty ltd - glyphosate present as the monoethanolamine salt - soluble concentrate - glyphosate present as the monoethanolamine salt glycine active 450.0 g/l - herbicide - almond | avocado | banana | band spraying | blueberry | camellia or tea | citrus | cotton - pre harvest | cotton - shielded spra - amaranth or amaranthus | annual phalaris | annual ryegrass | annual weeds | barbed wire grass | barley grass | barnyard grass - seed (echinochloa spp.) | barnyard or water grass | bathurst burr | bent grass - agrostis tenuis | black speargrass | brome grass | burr medic | button grass | calomba daisy | caltrop - tribulis terrestis | canary grass | capeweed | carpet grass | cat's ears or flatweeds | chickweed | columbus grass - seedling | couch | deadnettle | dock | erodium, crowfoot or storksbill | hoary cress or whiteweed | kikuyu grass | liverseed or urochloa grass | lovegrass | mintweed | native millet | noogoora burr | nutgrass - seasonal suppression | paspalum | paterson's curse | perennial phalaris - suppression | pigweed spp. | plantain | poa tussock - suppression | red natal grass | ryegrass | saffron thistle | scotch thistle | silver grass or rat's-tail fescue | sorghum | sorghum - stubble | sorghum grain | sorrel | soursob or oxalis | spear or black thistle | stink grass | subterranean clover | suga